Holista CollTech Limited Overview
Holista Colltech is a Perth-domiciled, Malaysia-operated natural health company whose economic engine is a mature, cash-generative dietary supplements franchise in Malaysia — anchored by the halal-certified PRISTIN® Omega-3 fish oil brand — wrapped around a portfolio of long-dated technology options. The options include patented ovine (sheep-derived) collagen and nano-collagen, which management positions as the world's only collagen extracted from disease-free Australian sheep using patented methods; low-glycaemic-index food ingredient technologies (low-GI bread, noodles, flatbreads and a sugar substitute); natural sanitisers; and an embryonic agricultural biotechnology line (nano urea, nano copper, poultry probiotics). Supplements generated 90.6% of FY2025 revenue and Malaysia 97.4%, so the investment case is effectively a small Malaysian consumer health distributor carrying ASX listing costs, legacy litigation scars (ASIC penalty, ProImmune judgment) and an optionality layer whose value hinges on the Regenerex wound-care supply agreement and the Ovicoll collagen joint venture in Collie, Western Australia.
Company's own description (paraphrased from FY2025 Annual Report)
Holista describes itself as a research-driven biotech company formed from the merger of Holista Biotech Sdn Bhd and Colltech Australia Ltd, headquartered in Perth and operating primarily in Australia and Malaysia. Its stated core purpose is to research natural solutions that help people live healthier lives. The company highlights four strands: (i) proprietary food-ingredient solutions that allow manufacturers to make healthier products without chemicals and without compromising taste, odour or mouthfeel — commercialised to date as low-GI bread, noodles/pasta, flatbreads and a low-calorie/low-GI sugar substitute; (ii) ovine collagen, where it claims to be the only producer globally using disease-free Australian sheep and patented extraction methods; (iii) leadership in Malaysian distribution of natural health supplements; and (iv) a range of all-natural, non-toxic sanitisers for consumer and industrial use (FY2025 Annual Report, "About Us" and "Corporate Profile").
The principal activities listed in the FY2025 Directors' Report are the manufacture and sale of "health-style" products across Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control/Agriculture.
Independent characterisation
Stripped of its biotech framing, Holista in FY2025 is a branded consumer health distributor in Malaysia with an attached technology-licensing ambition. Three facts dominate the economics:
-
Product concentration. Supplements generated A$5.22m of A$5.76m FY2025 revenue (90.6%) and A$0.77m segment profit before tax, while all other operating segments combined generated A$0.54m of revenue (FY2025 Annual Report Note 3).
-
Channel concentration. Within Supplements, one single external distributor accounted for 92% of segment revenue in FY2025 (91% in FY2024), which equates to roughly 83% of group revenue. Food Ingredients relies on a few customers for 85% of segment revenue, and Ovine Collagen relies on one customer for 100% (FY2025 Annual Report Note 3, "Major customers").
-
Geographic concentration. Malaysia contributed A$5.62m (97.4%) of FY2025 revenue; Australia A$0.15m (2.6%), all from ovine collagen; the United States recorded no external revenue (FY2025 Annual Report Note 4).
Business and revenue model
| Dimension | Characterisation | Evidence |
|---|---|---|
| Revenue model mix | ~100% product sales recognised at a point in time; royalty income is a disclosed accounting policy, but no material royalty revenue was reported in FY2025 | FY2025 Annual Report Note 4 ("Goods transferred at a point in time: 5,764,055") |
| Product vs service vs subscription vs licensing | Product: ~100%. Service: nil. Subscription: nil. Licensing: nil reported (Regenerex agreement structured as supply with exclusivity; Ovicoll JV to pay an 8% royalty to Holista from future JV sales) | FY2025 Annual Report; JV announcement 5 May 2026 |
| Value chain position | Supplements: brand owner and marketer using contract manufacturing and third-party distribution (fish oil sourced from South America, processed in Norway, per 2021 management commentary). Collagen: vertically integrated extractor (legacy Collie plant, now being replaced via JV). Food ingredients: B2B formulator/supplier | FY2025 Annual Report; NutraIngredients-Asia, April 2021 |
| Customer types | Malaysian pharmacy retail via a master distributor; Holista-owned webstores (Alterni.com, Holista.global per September 2025 announcement); B2B food and beverage manufacturers; one B2B collagen customer; US wound-care partner (Regenerex); agricultural customers in Malaysia (pilot stage) | FY2025 Annual Report; ASX announcement 11 September 2025 |
| End-markets | Consumer health supplements (Malaysia); food ingredients (Malaysia/ASEAN); cosmetic-grade collagen (export); medical wound care (US, pre-commercial); agriculture (Malaysia, pilot) | FY2025 Annual Report |
Revenue recognition includes rights of return and volume rebates. At 31 December 2025, right-of-return assets were A$339,437 and refund liabilities were material (A$862,592 at 30 June 2025). FY2024 revenue was depressed by returns from a major chain pharmacy, so returns accounting is a live earnings-quality consideration (FY2024 Appendix 4E; 1H FY2025 Interim Report Note 7).
Strategy
Stated strategy (FY2025 Annual Report, paraphrased)
The Chairman characterises FY2025 as a year of financial stabilisation, balance-sheet repair and strategic reset under new leadership. Management's stated priorities are operational discipline, cost management and prudent capital allocation, alongside developing new commercial applications for the group's technologies. The 1H FY2025 review added digital marketing and a strategic shift toward high-value pharmaceutical collagen applications.
Initiatives (last 24 months)
| Initiative | Date | Description | Status / target | Source |
|---|---|---|---|---|
| Regenerex wound-care supply agreement | 26 Aug 2025 | Exclusive worldwide wound-care rights to Holista's ovine and nano-collagen; Regenerex funds clinical trials and FDA approvals; co-development with shared IP | First order US$51,700 (24 Dec 2025). Minimum purchases: US$3m (2026), US$6m (2027), US$9m p.a. from 2028. No penalty for shortfall other than Holista's termination right | 1H FY2025 Interim Report Note 1; Appendix 4C Jan 2026 |
| Ovicoll JV (Collie) | 5 May 2026 | 50:50 JV with Swang Chai Chuan (HKEX: 2321); SCC contributes RM5m (~A$1.6m); Holista manages operations; Holista option to move to 75% over five years; JV pays Holista an 8% royalty on gross sales, capped at 20% of JV pre-tax profit; Holista retains IP | Land acquired June 2026; operations targeted December 2026 (FY2025 Annual Report said 2H 2026, subject to funding) | ASX announcements 5 May and 19 Jun 2026; Antara/ACN Newswire |
| Collagen manufacturing consolidation in Australia | FY2025 | Replace closed Collie plant with an asset-light modular facility incorporating nano-element capability; Sarawak plan dropped | In progress via Ovicoll | FY2025 Annual Report |
| Agricultural biotechnology | FY2025 onward | Nano urea, nano copper, poultry probiotics in Malaysia | A$9,410 revenue FY2025; A$23,484 in 1H FY2026 | FY2025 Annual Report; 1H FY2026 |
| Odour management solutions | 2,026 | New product line | Initial revenue "may" be recorded in 2026 | FY2025 Annual Report |
| Digital and marketplace expansion (Supplements) | 2025–2026 | Expanded online marketplace presence and stronger sales team | Supplements +12.2% in 1H FY2026 | 1H FY2026 Half Year Review |
| Anti-counterfeit action | 11 Sep 2025 | Police report over counterfeit PRISTIN sold on e-commerce platforms; engagement with regulators and the Malaysian Muslim Consumer Association | Ongoing | ASX announcement |
| Capital management | Mar 2025 – Jul 2026 | A$1.55m convertible notes; A$2.295m placement; A$370,724 Powerwind convertible loan | Completed | FY2025 Annual Report; ASX announcements |
| ESG / sustainability commitments | — | No quantified commitments disclosed | — | — |
| Cost programmes with targets | — | Qualitative cost discipline only; no numerical targets | — | — |
Medium-term targets and guidance
No formal financial guidance has been issued. The only quantified forward figures are the Regenerex minimum purchase commitments. These are not guaranteed: there is no financial penalty if Regenerex falls short, and the company itself flags the risk to its cash flow projections (1H FY2025 Interim Report, going concern note). Against a 2026 minimum of US$3m, Ovine Collagen interim revenue in 1H FY2026 appears immaterial. The 2026 commitment is therefore at high risk of not being met in calendar 2026.
Products & Services
Pricing is generally not disclosed in filings. Where third-party retail prices are cited, they are labelled.
Supplements
| Product / brand | Description & capabilities | Target customer | Launch / latest | Pricing | Source |
|---|---|---|---|---|---|
| PRISTIN® Omega-3 Fish Oil 1200mg softgel | Halal-certified Omega-3 (EPA/DHA) fish oil; flagship product; sold through MOH-licensed pharmacies | Malaysian adult consumers, including Muslim consumers | Long-standing (pre-2012) | 2021 retail price RM67.60 per 30 capsules, cited by trade press as the most expensive in Malaysia | ASX announcement 11 Sep 2025; NutraIngredients-Asia, Apr 2021 |
| PRISTIN® GOLD Omega-3 Fish Oil 1200mg softgel | Premium variant of the flagship line | Same | — | — | ASX announcement 11 Sep 2025 |
| PRISTIN® MOPL (Marine Omega Phospholipids) | Third-generation herring-roe phospholipid Omega-3 (650mg Omega-3 per gel), claimed to have higher absorption | Premium consumers | c.2015 launch (date approximate) | — | The Edge Malaysia; NutraIngredients-Asia |
| PRISTIN® Omega-3 gummies (kids) | Children's Omega-3 gummy | Parents and children | Planned 2Q 2021 | — | NutraIngredients-Asia, May 2021 |
| SKNPRO Collagen | Collagen beauty supplement | Consumers | Launched FY2024 | — | FY2024 Appendix 4E |
| PROBIO-30 | Probiotic supplement | Consumers | Launched FY2024 | — | FY2024 Appendix 4E |
| Omega-3 (new registration) | Omega-3 registration initiated in FY2024 (market not specified) | — | FY2024–25 | — | FY2024 Appendix 4E |
| Water-soluble vitamin D platform | Patent filed in 2019 for a platform making fat-soluble actives water-soluble; management claimed up to 80x better absorption (unvalidated) | Consumers | Planned 2021 | — | NutraIngredients-Asia, May 2021 |
| Emulin M / Emulin C | Products previously listed on the Australian Register of Therapeutic Goods (ARTG 300145, 300147); listings cancelled under s30(2)(f) | — | Cancelled | — | TGA |
Distribution: one external distributor handles 92% of Supplements revenue. Online sales via Holista-owned webstores (Alterni.com, Holista.global) are noted in the 11 September 2025 counterfeit-product announcement.
Ovine Collagen
| Product | Description & capabilities | Target customer | Status | Pricing | Source |
|---|---|---|---|---|---|
| Ovine collagen (cosmetic grade, 300 kDa intact) | Collagen extracted from disease-free Australian sheep using patented methods; halal-certified; positioned as an alternative to bovine/porcine collagen (avoids BSE concerns, culturally acceptable) | Cosmetic manufacturers (one customer = 100% of segment revenue) | Legacy Collie plant ceased in late 2024; sales drawn from existing stock | — | FY2025 Annual Report; Regenerex press release, Sep 2025 |
| Nano-collagen (medical) | Patented/patent-pending nano-collagen for chronic wound care; IP filings underway | Regenerex Pharma (exclusive worldwide wound-care rights) | Pre-commercial; first Regenerex order US$51,700 received 24 Dec 2025 | Minimum purchase commitments: US$50k (2025), US$3m (2026), US$6m (2027), US$9m p.a. from 2028 | 1H FY2025 Interim Report; Appendix 4C Jan 2026 |
| Ovine exosomes | Research programme commenced 2023 | Research | Early-stage | — | 1H FY2023 Half Year Review |
Food Ingredients
| Product | Description | Target customer | Status | Source |
|---|---|---|---|---|
| Low-GI bread premix (incl. GI Lite™) | Lowers the glycaemic index of baked goods without changing taste or mouthfeel; adopted by Costanzo's Bakery (US) in 2020 | Bakeries and QSR chains | FY2025 segment revenue −49.7% | FY2021 4E; FY2025 Annual Report |
| Low-GI noodles/pasta and flatbreads | Low-GI formulations | Noodle and flatbread manufacturers | Active | FY2025 Annual Report |
| Low-calorie / low-GI sugar substitute | Sugar reduction ingredient | F&B manufacturers | Active | FY2025 Annual Report |
| Reduced-sodium salt and low-fat frying solutions | Earlier suite (reduced-sodium salts, low-fat fried foods) | F&B manufacturers | Current status not disclosed | ASX release, 12 May 2020 |
| Healthier croissant (Berjaya Country Farms / Starbucks Malaysia) | Healthier croissant formulation; first commercial order announced | Café chains | Historical (c.2021–22) | Stocklight register; FY2021 4E |
| Post-biotic nutrition | Under evaluation | — | Development | FY2025 Annual Report Outlook |
Infection Control / Agriculture
| Product | Description | Status | Source |
|---|---|---|---|
| NatShield™ sanitiser | Alcohol-free, plant-based sanitiser using Path-Away®; tested >99.99% against a COVID-19 surrogate (feline coronavirus). Subject of ASIC misleading-statement findings | Segment revenue negligible since 2022 | ASIC 21-202MR; ACN Newswire |
| Nano silver disinfectant | All-natural disinfectant (test results announced) | Status not disclosed | Stocklight register |
| "List N" disinfectant (US) | US EPA List N disinfectant launch announced December 2020 | Status not disclosed | ASX announcement 11 Dec 2020 |
| Nano urea | Agricultural nano-fertiliser | Pilot-to-recurring orders: 1H FY2026 sales A$23,484 (with probiotics) | 1H FY2026 Half Year Review |
| Nano copper | Agricultural nano-input | Pilot orders FY2025 | FY2025 Annual Report |
| Poultry probiotics | Feed probiotic | Pilot orders FY2025; building in 2026 | FY2025 Annual Report; 1H FY2026 |
| Odour management solutions | Planned revenue line | Expected 2026 | FY2025 Annual Report Outlook |
Financial Narrative
Data provenance. FY2024–FY2025 figures are from audited statements (FY2025 Annual Report). FY2021–FY2023 revenue and net loss are from company Appendix 4E commentary, cross-checked against TipRanks. FY2021–FY2023 pre-tax income is from TipRanks only.
Income statement — 5-year summary
Sources: FY2021 Appendix 4E (28 Feb 2022); FY2022 Appendix 4E (28 Feb 2023); FY2024 Appendix 4E (28 Feb 2025; FY2023 comparatives: revenue A$5,946,909, attributable loss A$4,805,763); FY2025 Annual Report. FY2021–FY2023 EPS computed from aggregator weighted average share counts (275.35m, 276.82m, 278.80m). FY2024 pre-tax figure is continuing operations only (A$68,573). Discrepancy: company commentary rounds the FY2021 net loss to A$1.3m and the FY2022 loss to A$1.5m; TipRanks shows A$1.26m and A$1.45m.
Revenue CAGR FY2021–FY2025: −7.9% p.a. (A$8.02m to A$5.76m).
Detailed income statement, FY2024–FY2025 (A$)
Source: FY2025 Annual Report, consolidated statement of profit or loss. Gross profit is computed as revenue less raw materials (net of inventory movements) less distribution costs, which reconciles to the company's stated gross margins of 42% (FY2024) and 45% (FY2025).
Commentary. The headline FY2025 loss of A$0.95m masks a materially improved operating core. Excluding the A$1.09m ASIC cost provision and approximately A$0.395m of ProImmune legal fees (FY2025 Annual Report), adjusted pre-tax profit would have been roughly +A$0.58m. That figure, however, still includes A$0.83m of credit-loss impairment reversals (debt recoveries, notably from related party iGalen Inc). Stripping both legal items and recoveries leaves an underlying pre-tax loss of approximately A$0.25m. This aligns with management's statement that Malaysian operations earned A$889,000 pre-tax, or approximately A$152,000 excluding non-recurring recoveries (FY2025 Chairman's Letter).
The 3-point gross margin expansion is attributed to ringgit strength, pricing discipline and cost control. Employee costs fell 17% and advertising fell 37%. FY2024's near-breakeven result was similarly flattered by A$1.29m of impairment reversals and recoveries, including A$560,000 from loans and A$534,000 from trade receivables (FY2024 Appendix 4E).
The structural inflection is therefore modest. Holista has moved from structurally loss-making (FY2020–FY2023) to approximately breakeven on an underlying basis. Recurring recoveries, which cannot persist indefinitely, have masked continued losses in Food Ingredients and Corporate.
Interim performance (A$)
Sources: 1H FY2025 Interim Report; 1H FY2026 Half Year Review. The 1H FY2026 net loss includes approximately A$2.66m of one-off costs from the ProImmune settlement. Excluding these, the company reports underlying profit after tax of approximately A$0.095m.
Quarterly trading, 2026 (A$)
Sources: Appendix 4C reports (30 Jan 2026, 28 Apr 2026, 30 Jul 2026). Q4 FY2025 total revenue and Q1 FY2026 net operating cash flow were not explicitly retrieved (zeros are placeholders); Q1 operating cash flow was described as a net outflow driven by inventory and legal fees. Q2 FY2026 operating outflow includes the US$1.0m initial ProImmune payment. Unused financing facilities stood at A$1.45m at 30 June 2026.
Balance sheet (A$)
Sources: FY2025 Annual Report; 1H FY2025 Interim Report. Total equity at 31 December 2023 was −A$3,386,159 (statement of changes in equity).
Debt composition (31 Dec 2025): current borrowings are predominantly Malaysian banker's acceptances (A$1.25m at 30 June 2025), plus a CIMB term loan secured over Malaysian freehold land and buildings (carrying value A$700,610) and small related-party loans. Cash of A$1.10m was held as term deposits. Security deposits of A$355,366 are restricted cash pledged to Malaysian banks (FY2025 Annual Report Notes 8, 13, 14, 18).
Commentary. FY2025 was a balance-sheet repair year. Equity raised totalled A$3.85m (A$1.55m convertible notes converted plus the A$2.295m placement), moving total equity from −A$3.37m to −A$0.42m and turning the group to net cash. The repair was immediately consumed in 2026: the US$1.8m ProImmune settlement (approximately A$2.66m expensed) and the A$1.09m ASIC costs claim (provided for in FY2025, still payable) exceed the year-end cash balance. Cash fell to A$526,000 by 30 June 2026, and the final US$800,000 instalment was paid in July 2026, partly funded by a A$370,724 convertible loan from Powerwind Plantation Sdn Bhd (ASX announcement, 17 July 2026).
The persistent negative NCI (−A$1.54m) indicates accumulated losses in partly owned subsidiaries; the subsidiaries involved are not identified in retrieved material.
Cash flow (A$)
Source: FY2025 Annual Report, consolidated statement of cash flows.
Commentary. Excluding the A$900,000 ASIC penalty instalment in each year, operating cash flow was approximately −A$114,000 in FY2024 and −A$626,000 in FY2025. FY2025 was affected by a A$290,000 inventory build and legal fees. Capex is negligible (A$23,353), so the business is asset-light, but it lacks the scale to self-fund the collagen strategy, which has been externalised to the Ovicoll JV partner. Banker's acceptance facilities roll over at roughly A$6m per year (gross borrowings and repayments), underscoring reliance on Malaysian trade finance.
Ratios
Computed from FY2025 Annual Report data. ROE, ROIC and debt/equity are not meaningful because equity is negative in both years (and attributable equity was only A$1.12m at end-FY2025). A full cash conversion cycle is not computable because payables include non-trade items (refund liabilities, ASIC provision); trade payables were A$1.84m at 30 June 2025.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key products/services |
|---|---|---|
Supplements | Manufacture (via contract) and wholesale distribution of dietary supplements in Malaysia | PRISTIN® Omega-3 range, PROBIO-30, SKNPRO Collagen, other Total Health-branded supplements |
Ovine Collagen | Manufacture and distribution of cosmetic-grade collagen; medical-grade/nano-collagen development | Ovine collagen (300 kDa intact), nano-collagen |
Food Ingredients | Manufacture and wholesale distribution of healthy food ingredients | Low-GI premixes (bread, noodles, flatbread), sugar substitute, reduced-sodium and reduced-fat solutions |
Infection Control / Agriculture | Natural sanitisers (legacy) and agricultural biotechnology (new) | NatShield and natural disinfectants; nano urea, nano copper, poultry probiotics |
Corporate | Head office, listing and legal costs | — |
Segment revenue (AUD)
| Segment revenue (AUD) | FY2024 | FY2025 |
|---|---|---|
Supplements | 4,686,963 | 5,222,652 |
Ovine Collagen | 148,290 | 148,529 |
Food Ingredients | 762,974 | 383,464 |
Infection Control / Agriculture | 12 | 9,410 |
Total external revenue | 5,598,239 | 5,764,055 |
Revenue by Segment (AUD)
| Segment PBT (AUD) | FY2024 | FY2025 |
|---|---|---|
Supplements | 118,767 | 772,615 |
Ovine Collagen | -219,952 | 16,287 |
Food Ingredients | -441,063 | -347,543 |
Infection Control / Agriculture | 560,077 | 780,474 |
Corporate | 66,599 | -2,130,380 |
Group PBT (continuing) | -84,428 | -908,547 |
Segment Revenue
| Segment | FY2025 revenue growth YoY (%) | FY2025 PBT margin (%) | FY2024 contribution (%) | FY2025 contribution (%) |
|---|---|---|---|---|
Supplements | 11.4 | 14.8 | 83.7 | 90.6 |
Ovine Collagen | 0.2 | 11.0 | 2.6 | 2.6 |
Food Ingredients | -49.7 | -90.6 | 13.6 | 6.7 |
Infection Control / Agriculture | — | — | 0.0 | 0.2 |
Interim segment revenue (AUD)
| Interim segment revenue (AUD) | 1H FY2024 | 1H FY2025 | 1H FY2026 |
|---|---|---|---|
Supplements | 2,186,532 | 2,593,877 | 2,910,000 |
Ovine Collagen | 46,540 | 90,394 | 0 |
Food Ingredients | 428,292 | 204,889 | 0 |
Infection Control / Agriculture | 12 | 0 | 23,484 |
Total revenue | 2,661,376 | 2,889,160 | 2,990,000 |
Segment Overview — Supplements
| Segment | Total assets | Total liabilities | Net assets/(liabilities) |
|---|---|---|---|
Supplements | 3,102,790 | -2,854,542 | 248,248 |
Ovine Collagen | 68,534 | -1,597,720 | -1,529,186 |
Food Ingredients | 2,613,017 | -4,520,826 | -1,907,809 |
Infection Control / Agriculture | 1,246 | -352,446 | -351,200 |
Corporate (incl. eliminations) | 87,847 | 3,304,029 | 3,121,879 |
Group | 5,873,435 | -6,291,503 | -418,068 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 8.02 | 8.24 | 5.95 | 5.60 | 5.76 |
Revenue growth YoY (%) | 12.9 | 2.7 | -27.8 | -5.9 | 3.0 |
Pre-tax income (AUD Mn) | -1.20 | -1.36 | -4.85 | 0.07 | -0.91 |
Net income attributable (AUD Mn) | -1.26 | -1.45 | -4.81 | -0.08 | -0.95 |
Net margin (%) | -15.7 | -17.6 | -80.8 | -1.5 | -16.5 |
Basic/diluted EPS (A$ cents) | -0.46 | -0.52 | -1.72 | -0.03 | -0.29 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement (AUD)
| Line item (AUD) | FY2024 | FY2025 |
|---|---|---|
Revenue from contracts with customers | 5,598,239 | 5,764,055 |
Other income | 65,410 | 26,756 |
Raw materials and consumables (net of inventory change) | -2,782,867 | -2,781,725 |
Distribution and other costs of sales | -441,292 | -372,124 |
Gross profit (company definition) | 2,374,080 | 2,610,206 |
Advertising and promotion | -405,574 | -254,156 |
Consultancy and professional fees | -98,432 | -517,922 |
Employee benefits | -2,152,019 | -1,785,964 |
Research and development | -72,064 | -36,066 |
Impairment reversal / (expense), net | 1,286,394 | 829,569 |
Foreign exchange gain / (loss) | -165,168 | 14,570 |
Other expenses | -509,574 | -544,123 |
ASIC litigation provision | 0 | -1,090,000 |
Share-based payments | -33,479 | 0 |
EBITDA (computed) | 289,574 | -747,130 |
Depreciation and amortisation | -101,553 | -53,989 |
EBIT / operating income (computed) | 188,021 | -801,119 |
Finance costs | -119,448 | -107,428 |
Profit / (loss) before tax (continuing) | 68,573 | -908,547 |
Income tax expense | -171,579 | -42,834 |
Discontinued operations | 15,855 | 0 |
Net loss | -87,151 | -951,381 |
Attributable to owners | -84,214 | -948,921 |
Margin (%)
| Margin (%) | FY2024 | FY2025 |
|---|---|---|
Gross margin | 42.4 | 45.3 |
EBITDA margin | 5.2 | -13.0 |
Operating (EBIT) margin | 3.4 | -13.9 |
Pre-tax margin | 1.2 | -15.8 |
Net margin | -1.5 | -16.5 |
Income Statement (AUD) and Margin Analysis (%)
| Metric (AUD) | 1H FY2024 | 1H FY2025 | 1H FY2026 |
|---|---|---|---|
Revenue | 2,661,376 | 2,889,160 | 2,990,000 |
Gross margin (%) | 42 | 41.9 | 44.3 |
Profit / (loss) before tax | -907,141 | -277,195 | 0 |
Net loss after tax | -981,568 | -296,569 | -2,560,000 |
Basic EPS (A$ cents) | -0.35 | -0.09 | 0 |
Cash Flow (AUD)
| Metric (AUD) | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 |
|---|---|---|---|
Revenue | 0 | 1,490,000 | 1,500,000 |
Customer receipts | 1,700,000 | 1,310,000 | 1,480,000 |
Net operating cash flow | 238,000 | 0 | -1,290,000 |
Closing cash | 2,160,771 | 1,944,000 | 526,000 |
Balance Sheet (AUD)
| Line item (AUD) | 31 Dec 2024 | 30 Jun 2025 | 31 Dec 2025 |
|---|---|---|---|
Cash and cash equivalents | 21,720 | 41,747 | 2,160,771 |
Trade and other receivables | 1,031,049 | 960,145 | 950,606 |
Inventories | 810,086 | 818,030 | 1,099,817 |
Total current assets | 2,559,513 | 2,792,011 | 5,112,047 |
Property, plant and equipment | 746,263 | 734,994 | 741,038 |
Goodwill and intangibles | 14,052 | 7,875 | 5,989 |
Total assets | 3,341,894 | 3,553,055 | 5,873,435 |
Trade and other payables | 4,333,967 | 3,452,933 | 4,434,150 |
Borrowings — current | 1,314,826 | 1,302,023 | 1,166,799 |
Borrowings — non-current | 428,525 | 415,230 | 404,094 |
Total borrowings | 1,743,351 | 1,717,253 | 1,570,893 |
Net debt / (net cash) | 1,721,631 | 1,675,506 | -589,878 |
Total current liabilities | 6,264,634 | 5,219,122 | 5,880,895 |
Total liabilities | 6,709,614 | 5,647,082 | 6,291,503 |
Working capital | -3,705,121 | -2,427,111 | -768,848 |
Equity attributable to owners | -1,729,404 | -528,528 | 1,119,389 |
Non-controlling interest | -1,638,316 | -1,565,499 | -1,537,457 |
Total equity | -3,367,720 | -2,094,027 | -418,068 |
Cash Flow (AUD) (Annual)
| Line item (AUD) | FY2024 | FY2025 |
|---|---|---|
Receipts from customers | 6,625,839 | 5,844,498 |
Payments to suppliers and employees | -6,445,800 | -6,372,371 |
ASIC penalty and related costs | -900,000 | -900,000 |
Operating cash flow | -1,013,745 | -1,526,003 |
Capex (PP&E) | -7,040 | -23,353 |
Free cash flow (OCF − capex) | -1,020,785 | -1,549,356 |
Net investing cash flow | 692,118 | -176,359 |
Proceeds from share issues | 0 | 3,847,381 |
Net borrowings / (repayments) | 377,547 | -191,830 |
Net financing cash flow | -143,754 | 3,647,786 |
Dividends paid | 0 | 0 |
Share buybacks | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 |
|---|---|---|
ROA (%, net loss / average assets) | -2.6 | -20.6 |
Current ratio (x) | 0.41 | 0.87 |
Net debt / EBITDA (x) | 5.9 | — |
Interest coverage (EBIT / finance costs, x) | 1.6 | -7.5 |
Asset turnover (x) | 1.57 | 1.25 |
Inventory days (on raw materials consumed) | 104 | 131 |
Region revenue (AUD)
| Region revenue (AUD) | FY2024 | FY2025 |
|---|---|---|
Malaysia | 5,449,949 | 5,615,526 |
Australia | 148,290 | 148,529 |
United States | 0 | 0 |
Total | 5,598,239 | 5,764,055 |
Revenue by Region (%)
| Region (%) | FY2025 growth YoY (%) | FY2025 share (%) |
|---|---|---|
Malaysia | 3.0 | 97.4 |
Australia | 0.2 | 2.6 |
Revenue by Region (AUD)
| Region PBT (AUD) | FY2024 | FY2025 |
|---|---|---|
Australia | -513,250 | -1,795,490 |
Malaysia | 794 | 889,405 |
United States | 428,028 | -2,462 |
Group | -84,428 | -908,547 |
Share price metric (AUD)
| Share price metric (AUD) | 2024 | 2025 | 2026 YTD |
|---|---|---|---|
Opening price | 0.013 | 0.013 | 0.086 |
Closing / latest price | 0.013 | 0.086 | 0.067 |
Period change (%) | 0 | 561.5 | -22.1 |
Period high | 0.02 | 0.11 | 0.089 |
Period low | 0.01 | 0.013 | 0.05 |
Share Price & Returns
| Horizon | Approximate return | Note |
|---|---|---|
1-year | ~−20% (from ~A$0.08–0.09 in October 2025 to ~A$0.067) | Approximate |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Market capitalisation | ~A$24.6m | Price × shares |
Enterprise value | ~A$25.7m | Market cap + FY2025 borrowings (A$1.57m) − 30 Jun 2026 cash (A$0.53m); mixed-date approximation |
EV / Sales (TTM) | ~4.4x | TTM revenue A$5.87m (FY2025 − 1H FY2025 + 1H FY2026) |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None; no broker coverage identified |
Dividends | None paid or declared in FY2024, FY2025 or 1H FY2026; no dividend policy |
Credit ratings (Moody's, S&P, Fitch) | Not rated |
Debt maturity profile | Current borrowings A$1.17m (banker's acceptances, rolling); non-current A$0.40m (CIMB term loan, secured); Powerwind convertible loan A$370,724 (2026; terms not fully verified) |
Options / performance rights | None outstanding at the FY2025 report date |
Analyst Conclusions
Management outlook (FY2025 Annual Report and 2026 releases)
Management expects to maintain operational discipline and cost control. Specific expectations are:
-
Continued ringgit strength supporting AUD-translated revenue.
-
The Collie plant commencing operations in 2H 2026 (targeted December 2026 per the June 2026 announcement), subject to funding and execution.
-
Possible initial revenue from agricultural biotechnology and odour management in 2026.
No quantitative earnings guidance has been given. There is no consensus.
Bull case
-
Regenerex scales. Even 50% of the 2027 minimum commitment (US$6m) would roughly add revenue equal to current group revenue at likely high margins. This would transform Holista from a Malaysian distributor into a medical collagen supplier.
-
Underlying breakeven is real. 1H FY2026 underlying profit after tax of ~A$0.095m, a 44% gross margin and 12% Supplements growth suggest the core can self-fund once legal costs end. ProImmune is now closed and the ASIC penalty is paid.
-
Capital-light optionality. SCC funds Ovicoll, Holista receives an 8% royalty plus a path to 75% ownership, and existing shareholders retain IP upside without bearing capex.
Bear case
-
Liquidity is precarious. Cash of A$526,000 at 30 June 2026, the final US$800,000 settlement payment in July and the unpaid ~A$1.09m ASIC costs claim make a dilutive raise likely in the near term, at a share price ~4x below the 2025 high-water mark of A$0.11.
-
Concentration risk is extreme. About 83% of revenue flows through one Malaysian distributor; loss or renegotiation of that contract would remove most of the business. FY2024's pharmacy-chain returns show how fragile the channel is.
-
Collagen promises carry a credibility discount. There is no shortfall penalty in the Regenerex contract, and the 2026 minimum looks unattainable against orders of US$51,700 to date. Regenerex is a related party and a small OTC company. Holista's disclosure history includes court-found misleading statements, and collagen revenue has been ~A$0.15m per year.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst |
|---|---|
| By 31 Oct 2026 | Q3 FY2026 Appendix 4C: cash after the final ProImmune payment; any capital raise |
| Q4 2026 | Resolution or payment terms of the ASIC costs claim |
| Dec 2026 | Ovicoll Collie plant commissioning |
| Through 2026–27 | Regenerex order flow against the US$3m 2026 minimum; any FDA submissions |
| Feb–Mar 2027 | FY2026 Appendix 4E and Annual Report; going-concern status |
| Ongoing | Supplements growth versus MYR moves; distributor contract status; agriculture order conversion |
| Ongoing | Conversion of the Powerwind loan; changes in substantial holdings (Neo Health, SCC-linked parties) |
Analyst verdict
Holista Colltech is best understood as two businesses sharing one listing.
The first is a modest but genuinely improving Malaysian supplements distributor. PRISTIN remains a credible premium halal brand, gross margins have expanded to the mid-40s, and the Malaysian operations produced an underlying pre-tax profit in FY2025 for the first time in several years. Management's cost discipline is visible: KMP pay fell by two-thirds, employee costs fell 17%, and the CEO works for a nominal A$1. On an underlying basis the business is near breakeven, a meaningful improvement on the A$1–5m annual losses of FY2020–FY2023.
The second is an option portfolio around ovine and nano-collagen. Its value depends almost entirely on two partners: Regenerex, a related-party OTC company with no penalty for missing its minimum purchases, and Swang Chai Chuan, which funds the Collie plant in exchange for half the JV. The structure is sensibly capital-light. However, the gap between contracted minimums (US$3m in 2026) and actual orders (US$51,700) is large, and the plant does not yet exist.
The balance sheet is the binding constraint. Legal legacies have consumed approximately A$4.5m+ in penalties, settlements and provisions since 2024, wiping out the equity rebuilt through the 2025 raisings. With A$526,000 of cash at June 2026 and the ASIC costs claim outstanding, further dilution appears likely, and the auditor continues to flag a material uncertainty over going concern.
At roughly A$25m market capitalisation (about 4x trailing sales), the market already prices significant collagen success into a business whose provable earnings power is close to zero. Governance has improved since 2024, with an independent chair and a refreshed board, but committee functions remain undifferentiated, D&O insurance is absent, and key contracts are with related parties.
**Verdict: speculative, high-risk. Until those are visible, the asymmetry favours caution.
All figures in A$ unless stated. "Not publicly disclosed" denotes information not found in company filings or reliable public sources as of 10 October 2026. Aggregator-derived and approximate figures are labelled.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Qualifications | Shares held (31 Dec 2025) |
|---|---|---|---|---|---|
Lai Kwok Kin | Independent Non-Executive Chairman | Director 2024 (FY2024 fees shown); Chairman 24 Apr 2025 | ~40 years in journalism (Reuters Chief Correspondent, Malaysia & Brunei), equity research (Merrill Lynch head of Malaysia research), and investor relations/crisis communications; founded WeR1 group in 1999 | BA (Arts & Social Science), National University of Singapore; postgraduate diploma in Journalism, City University of London | 9,675,785 |
Leong Man Loong | Executive Director and CEO | Interim CEO 3 Jan 2025; CEO 3 Jul 2025 | Entrepreneur and inventor with ~30 years in nanotechnology, green chemistry and environmental technology; Executive Chairman of the SHEPROS Group (Malaysia) | BSc Mechanical Engineering (US) | 36,159,845 |
Gregory Pilant | Non-Executive Director (non-independent) | 26 Mar 2025 | Founder, CEO and Chairman of Regenerex Pharma (OTC: RGPX); founded Greystone Pharmaceuticals; led Stanley Pharmaceuticals, National Labs and MedStat; 30+ years in wound care | Not disclosed (University of Memphis Business Hall of Fame inductee) | 30,234,317 |
Robert Gemelli | Independent Non-Executive Director | 14 May 2025 | Perth-based entrepreneur: insurance (Federation Insurance), entertainment (GM, Entertainment Enterprises; own business in Broome); active ASX investor | — | 8,715,016 |
Sam Yee (Yee Yuen Keong) | Independent Non-Executive Director | 14 May 2025 | Melbourne consultant; former CEO, Gribbles Diagnostic; senior roles at Wyeth, Pfizer (Asia Pacific Marketing Director), Merck Serono, GSK and Roche | B.Pharm (University of Wales); MBA (University of Strathclyde) | 10,000 |
Jay Stephenson | Company Secretary | 1 Sep 2021 | 30+ years in business development; CFO/Company Secretary roles; NED of Liberty Metals and Pinnacle Minerals | — | — |
“—” = not publicly disclosed.
Directors' Remuneration
| KMP | FY2025 total (AUD) | FY2024 total (AUD) |
|---|---|---|
Lai Kwok Kin | 48,000 | 37,677 |
David Deloub (former Chairman, to 16 Apr 2025) | 22,500 | 60,000 |
Loren King (former NED, to 16 Apr 2025) | 18,000 | 48,000 |
Robert Gemelli | 15,000 | 0 |
Sam Yee | 15,000 | 0 |
Leong Man Loong (CEO) | 0 | 0 |
Gregory Pilant | 0 | 0 |
Rajen Manicka (director to 19 Mar 2024, then consultant) | 0 | 224,635 |
Total KMP | 118,500 | 370,312 |
Board & Management Changes
| Date | Change |
|---|---|
19 Mar 2024 | Dr Rajen Manicka disqualified for 4 years; ceases as director (consulting thereafter, not KMP in FY2025) |
3 Jan 2025 | Leong Man Loong appointed Executive Director and Interim CEO |
26 Mar 2025 | Gregory Pilant appointed NED |
16 Apr 2025 | David Deloub (Chairman) and Loren King (NED) resign |
24 Apr 2025 | Lai Kwok Kin becomes Independent Chairman |
14 May 2025 | Robert Gemelli and Sam Yee appointed independent NEDs |
3 Jul 2025 | Leong confirmed as CEO |
Major Shareholders
| Holder | Shares | % (approx.) | Basis | Source |
|---|---|---|---|---|
Galen Biomedical Inc | 58,514,245 | 20.99 (of ~279m shares at the time) | — | MarketIndex |
Leong Man Loong (CEO) | 36,159,845 | 9.8 | Director interest | FY2025 Annual Report |
Gregory Pilant | 30,234,317 | 8.2 | Director interest | FY2025 Annual Report |
Neo Health Sdn Bhd | 23,467,756 | 6.38 | Substantial holder notice, 11 Nov 2025 | Form 603, 13 Nov 2025 |
Lai Kwok Kin | 9,675,785 | 2.6 | Director interest | FY2025 Annual Report |
Robert Gemelli | 8,715,016 | 2.4 | Director interest | FY2025 Annual Report |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs Holista |
|---|---|---|
Supplements (Malaysia) | Blackmores (Kirin Holdings) | Larger multi-category brand with strong pharmacy presence |
Supplements (Malaysia) | Kotra Pharma (Appeton) | Local listed peer with broader consumer health range |
Supplements (Malaysia) | VitaHealth | Local supplement brand in pharmacy channel |
Supplements (Malaysia) | Scott's (Haleon) | Mass-market fish oil/cod liver oil |
Supplements (Malaysia) | Nutrilite (Amway), Herbalife | Direct-selling scale players |
Supplements (Malaysia) | Watsons / Guardian private labels | Low-price fish oil (RM19.90 vs PRISTIN RM67.60 in 2021 trade press) |
Collagen (ingredients) | Rousselot (Darling Ingredients) | Global bovine/porcine/marine collagen leader |
Collagen (ingredients) | Gelita | Global collagen peptides leader |
Collagen (ingredients) | Nitta Gelatin | Japanese collagen/gelatin producer |
Collagen (ingredients) | PB Leiner (Tessenderlo) | Gelatin and collagen peptides |
Collagen (medical / wound care) | Integra LifeSciences | Collagen-based regenerative wound products |
Collagen (medical / wound care) | Smith+Nephew | Advanced wound management |
Food ingredients (sugar/GI reduction) | Tate & Lyle, Ingredion, Cargill, Roquette | Global specialty ingredient majors |
Peer Comparison FY2025
| Company | Latest annual revenue (approx.) | Revenue growth | Margin profile | R&D intensity |
|---|---|---|---|---|
Holista Colltech (FY2025) | A$5.76m | 3.0% | GM 45%; net −16.5% | 0.6% |
Recent Developments
Discrepancy: * the 1H FY2026 review dates the final ProImmune payment to 10 July 2026, while the separate ASX announcement reporting it is dated 17 July 2026.
The Q3 FY2026 Appendix 4C is due by 31 October 2026.



